• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对新型囊性纤维化药物Trikafta的新反应。

Novel reaction to new cystic fibrosis medication Trikafta.

作者信息

Stashower Julian, Carr Patrick, Miller Virginia, Zlotoff Barrett

机构信息

University of Virginia School of Medicine Charlottesville VA USA.

Department of Dermatology University of Virginia School of Medicine Charlottesville VA USA.

出版信息

Clin Case Rep. 2021 May 4;9(5):e04116. doi: 10.1002/ccr3.4116. eCollection 2021 May.

DOI:10.1002/ccr3.4116
PMID:34026156
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8122137/
Abstract

We present a novel case of an urticaria multiforme-type drug reaction to the new cystic fibrosis medication Trikafta (elexacaftor + tezacaftor + ivacaftor). Equipped with this information, clinicians may be more prepared to counsel and treat patients if they experience similar symptoms after beginning Trikafta.

摘要

我们报告了一例对新型囊性纤维化药物Trikafta（依列卡福妥 + 替扎卡福妥 + 依伐卡托）产生多形性荨麻疹型药物反应的新病例。掌握了这些信息后，如果临床医生的患者在开始使用Trikafta后出现类似症状，他们可能会更有准备为患者提供咨询和治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/8122137/a96487eb3438/CCR3-9-e04116-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/8122137/a7b935bc2d2e/CCR3-9-e04116-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/8122137/57e8dbc7da9a/CCR3-9-e04116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/8122137/94135fd68f90/CCR3-9-e04116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/8122137/a96487eb3438/CCR3-9-e04116-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/8122137/a7b935bc2d2e/CCR3-9-e04116-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/8122137/57e8dbc7da9a/CCR3-9-e04116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/8122137/94135fd68f90/CCR3-9-e04116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/8122137/a96487eb3438/CCR3-9-e04116-g003.jpg

相似文献

1
Novel reaction to new cystic fibrosis medication Trikafta.对新型囊性纤维化药物Trikafta的新反应。
Clin Case Rep. 2021 May 4;9(5):e04116. doi: 10.1002/ccr3.4116. eCollection 2021 May.
2
Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis.依洛尤单抗治疗对高胆固醇血症患者认知功能的影响。
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221144211. doi: 10.1177/17534666221144211.
3
Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis.一名患有囊性纤维化的儿科患者因新型药物依列卡福/替扎卡福/依伐卡福出现多形性荨麻疹样皮疹。
JAAD Case Rep. 2021 Oct 25;18:71-73. doi: 10.1016/j.jdcr.2021.10.018. eCollection 2021 Dec.
4
The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.由于依伐卡托的存在，在人气道上皮细胞中，艾列卡托/替扎卡托/依伐卡托（三联疗法）对F508del-CFTR的挽救作用被低估了。
Eur Respir J. 2022 Feb 24;59(2). doi: 10.1183/13993003.00671-2021. Print 2022 Feb.
5
If At First You Don't Succeed, Trikafta Again.如果一开始你没有成功，那就再用三联疗法（Trikafta）。
J Pediatr Pharmacol Ther. 2022;27(5):467-469. doi: 10.5863/1551-6776-27.5.467. Epub 2022 Jul 6.
6
A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy.三联卡法托（Trikafta）综述：三联囊性纤维化跨膜传导调节因子（CFTR）调节剂疗法
Cureus. 2021 Jul 3;13(7):e16144. doi: 10.7759/cureus.16144. eCollection 2021 Jul.
7
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
8
Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype.依列卡福妥-替扎卡福妥-依伐卡托对携带F508del/未知基因型的囊性纤维化患者的治疗
Antibiotics (Basel). 2021 Jul 7;10(7):828. doi: 10.3390/antibiotics10070828.
9
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对具有 II 类 CFTR 基因突变（最常见的是 F508del）的囊性纤维化患者的校正治疗（含或不含增效剂）。
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.
10
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.

引用本文的文献

1
Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.调节剂难治性囊性纤维化：定义一个新兴高危人群的范围和挑战。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241297877. doi: 10.1177/17534666241297877.
2
Successful Desensitization With ELX/TEZ/IVA.使用ELX/TEZ/IVA成功脱敏。
J Pediatr Pharmacol Ther. 2024 Oct;29(5):539-543. doi: 10.5863/1551-6776-29.5.539. Epub 2024 Oct 14.
3
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.

本文引用的文献

1
Elexacaftor/Ivacaftor/Tezacaftor: First Approval.依伐卡托/埃乐卡福特/泰泽卡福特：首次批准。
Drugs. 2019 Dec;79(18):2001-2007. doi: 10.1007/s40265-019-01233-7.
2
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
3
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-445-泰泽卡托维瓦卡托联合治疗伴有一个或两个 Phe508del 等位基因的囊性纤维化患者。
依列卡福妥-替扎卡福妥-依伐卡托：用于囊性纤维化的改变人生的三联组合CFTR调节剂药物。
Pharmaceuticals (Basel). 2023 Mar 8;16(3):410. doi: 10.3390/ph16030410.
4
Newly Discovered Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review.新发现的前沿性囊性纤维化三联组合疗法：一项系统评价
Cureus. 2022 Sep 20;14(9):e29359. doi: 10.7759/cureus.29359. eCollection 2022 Sep.
5
Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis.糠秕马拉色菌性毛囊炎继发于囊性纤维化三联疗法治疗后。
Medicina (Kaunas). 2022 Sep 2;58(9):1204. doi: 10.3390/medicina58091204.
6
If At First You Don't Succeed, Trikafta Again.如果一开始你没有成功，那就再用三联疗法（Trikafta）。
J Pediatr Pharmacol Ther. 2022;27(5):467-469. doi: 10.5863/1551-6776-27.5.467. Epub 2022 Jul 6.
7
Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation.依利卓卡非特、泰他西卡非特和依伐卡非特：严重皮疹病例及脱敏治疗方法。
BMJ Case Rep. 2022 Mar 2;15(3):e247042. doi: 10.1136/bcr-2021-247042.
8
Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis.一名患有囊性纤维化的儿科患者因新型药物依列卡福/替扎卡福/依伐卡福出现多形性荨麻疹样皮疹。
JAAD Case Rep. 2021 Oct 25;18:71-73. doi: 10.1016/j.jdcr.2021.10.018. eCollection 2021 Dec.
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.
4
Urticaria multiforme.多形性荨麻疹
J Clin Aesthet Dermatol. 2013 Mar;6(3):34-9.
5
"Urticaria multiforme": a case series and review of acute annular urticarial hypersensitivity syndromes in children.“多形性荨麻疹”：儿童急性环状荨麻疹超敏综合征的病例系列及综述
Pediatrics. 2007 May;119(5):e1177-83. doi: 10.1542/peds.2006-1553.